Ars Pharmaceuticals Stock Net Income
| SPRY Stock | 10.97 0.52 4.53% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess ARS Pharmaceuticals' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Income | 7.2 M | 7.6 M | |
| Net Income From Continuing Ops | 7.2 M | 7.6 M | |
| Net Loss | -31.2 M | -29.7 M | |
| Net Income Per Share | 0.07 | 0.08 | |
| Net Income Per E B T | 0.87 | 0.78 |
ARS | Net Income | Build AI portfolio with ARS Stock |
ARS Pharmaceuticals Company Net Income Analysis
ARS Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current ARS Pharmaceuticals Net Income | 8 M |
Most of ARS Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ARS Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ARS Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ARS Pharmaceuticals is extremely important. It helps to project a fair market value of ARS Stock properly, considering its historical fundamentals such as Net Income. Since ARS Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ARS Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ARS Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ARS Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ARS Pharmaceuticals reported net income of 8 M. This is 97.66% lower than that of the Biotechnology sector and 88.58% lower than that of the Health Care industry. The net income for all United States stocks is 98.6% higher than that of the company.
ARS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ARS Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ARS Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ARS Pharmaceuticals by comparing valuation metrics of similar companies.ARS Pharmaceuticals is currently under evaluation in net income category among its peers.
ARS Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of ARS Pharmaceuticals from analyzing ARS Pharmaceuticals' financial statements. These drivers represent accounts that assess ARS Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ARS Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 192.3M | 340.8M | 521.8M | 1.0B | 1.2B | 810.8M | |
| Enterprise Value | 141.3M | 130.8M | 451.1M | 971.9M | 1.1B | 723.5M |
ARS Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ARS Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ARS Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ARS Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ARS Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ARS Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ARS Pharmaceuticals' value.| Shares | Southpoint Capital Advisors Lp | 2025-06-30 | 1.7 M | Fmr Inc | 2025-06-30 | 1.6 M | Aberdeen Group Plc | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | Wellington Management Company Llp | 2025-06-30 | 1.4 M | Octagon Capital Advisors Lp | 2025-06-30 | 1.4 M | Geode Capital Management, Llc | 2025-06-30 | 1.3 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 1.3 M | Rubric Capital Management Lp | 2025-06-30 | 1.3 M | Ra Capital Management, Llc | 2025-06-30 | 10.9 M | Deerfield Management Co | 2025-06-30 | 9.7 M |
ARS Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.56) % | ||||
| Operating Margin | (1.64) % | ||||
| Current Valuation | 945.32 M | ||||
| Shares Outstanding | 98.85 M | ||||
| Shares Owned By Insiders | 16.82 % | ||||
| Shares Owned By Institutions | 87.33 % | ||||
| Number Of Shares Shorted | 21.59 M | ||||
| Price To Book | 7.69 X | ||||
| Price To Sales | 7.96 X | ||||
| Revenue | 89.15 M | ||||
| Gross Profit | 114.87 M | ||||
| EBITDA | (3 M) | ||||
| Net Income | 8 M | ||||
| Total Debt | 42 K | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | 13.55 M | ||||
| Short Ratio | 10.04 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 28.83 | ||||
| Number Of Employees | 162 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 1.14 B | ||||
| Total Asset | 351.15 M | ||||
| Retained Earnings | (123.31 M) | ||||
| Working Capital | 310.86 M | ||||
| Net Asset | 351.15 M |
About ARS Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARS Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARS Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARS Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.